Ovarian Cancer Management

First-Line Systemic Therapy

The standard first-line systemic therapy for advanced ovarian cancer is carboplatin (AUC 5-6) plus paclitaxel (175 mg/m²) administered intravenously every 3 weeks for six cycles, as recommended by the European Society for Medical Oncology (ESMO) 1
Primary treatment options include paclitaxel 175 mg/m² IV over 3 hours followed by carboplatin AUC 5-6 IV on Day 1, repeated every 3 weeks for 6 cycles, with a Category 1 recommendation from the National Comprehensive Cancer Network (NCCN) 2, 1
For frail or elderly patients, weekly chemotherapy with paclitaxel 60 mg/m² and carboplatin AUC 2 can be considered as an alternative, offering better tolerability with lower rates of neuropathy, neutropenia, and alopecia, as suggested by the Annals of Oncology 1

Bevacizumab improves progression-free survival in stage III-IV ovarian cancer and should be considered in addition to standard chemotherapy, with an ESMO-MCBS score of 3, as recommended by the European Society for Medical Oncology (ESMO) 1, 3
Two bevacizumab regimens are recommended: paclitaxel 175 mg/m² IV, carboplatin AUC 6 IV, and bevacizumab 7.5 mg/kg IV on Day 1, repeated every 3 weeks for 5-6 cycles, followed by bevacizumab maintenance for up to 12 additional cycles, with a Category 3 recommendation from the National Comprehensive Cancer Network (NCCN) 2

For selected stage III patients with optimally debulked disease (residual disease ≤1 cm), IP chemotherapy is recommended, with a Category 1 recommendation from the National Comprehensive Cancer Network (NCCN), as it demonstrates a significant survival advantage 2
The IP regimen consists of paclitaxel 135 mg/m² IV over 24 hours on Day 1, followed by cisplatin 100 mg/m² IP on Day 2, and paclitaxel 60 mg/m² IP on Day 8, repeated every 3 weeks for 6 cycles, with a Category 1 recommendation from the National Comprehensive Cancer Network (NCCN) 2

Maintenance treatment with PARP inhibitors, with or without bevacizumab, is recommended based on molecular tumor characteristics, such as BRCA1/2 mutation status, with an ESMO-MCBS score of 4, as recommended by the European Society for Medical Oncology (ESMO) 1
For BRCA1/2-mutated tumors, olaparib for 2 years is recommended, with an ESMO-MCBS score of 4, as recommended by the European Society for Medical Oncology (ESMO) 1
For BRCA1/2-wild-type/HRD-positive tumors, niraparib for 3 years is recommended, with an ESMO-MCBS score of 3, as recommended by the European Society for Medical Oncology (ESMO) 1

For patients undergoing neoadjuvant chemotherapy followed by interval cytoreductive surgery, the same carboplatin-paclitaxel regimen is used, as recommended by the Annals of Oncology 1
Bevacizumab can be considered in the neoadjuvant setting, with a Level II, B evidence recommendation from the Annals of Oncology 1, 3

Secondary cytoreductive surgery should be considered for first relapse >6 months after completion of platinum-based chemotherapy in patients with complete resection at primary surgery, good performance status, and absence of ascites, as recommended by the Annals of Oncology 1
The traditional 6-month platinum-free interval cut-off has been discontinued in clinical practice, as many factors influence treatment-free interval and response to platinum, including histotype and BRCA1/2 mutation status, as recommended by the Annals of Oncology 1
For platinum-sensitive recurrent disease, bevacizumab (15 mg/kg) can be combined with carboplatin and gemcitabine or carboplatin and paclitaxel, followed by bevacizumab maintenance, as recommended by the Praxis Medical Insights 3
For platinum-resistant recurrent disease, bevacizumab can be combined with paclitaxel, pegylated liposomal doxorubicin, or topotecan, for patients who received ≤2 prior chemotherapy regimens, as recommended by the Praxis Medical Insights 3

Carboplatin dosing has equivalent efficacy to cisplatin when given at a 4:1 dose ratio, with less non-hematological toxicity but greater hematological toxicity, as reported by the British Journal of Cancer 5, 6
Optimal cycle number: available data does not support a benefit in overall survival from giving more than six courses of chemotherapy, as reported by the British Journal of Cancer 5, 6
Bevacizumab activity has shown activity in all histological subtypes of ovarian cancer, including less chemotherapy-responsive types like low-grade serous carcinoma and clear cell carcinoma, as recommended by the Praxis Medical Insights 3